Transferrin R2產(chǎn)品信息
別稱:Transferrin R2,TFR2
物種:Human
屬性:Protein
標(biāo)記:Unconjugated
內(nèi)毒素(Endotoxin)
Less than 0.1 EU per μg by the LAL method.
純度(Purity)
>95% as determined by SDS-PAGE.
制劑(Formulation)
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲(chǔ)(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
Transferrin R2分子背景
轉(zhuǎn)鐵蛋白受體蛋白2(TFR2)是一種單程II型膜蛋白,具有蛋白酶相關(guān)(PA)結(jié)構(gòu)域、M28肽酶結(jié)構(gòu)域和轉(zhuǎn)鐵蛋白受體樣二聚化結(jié)構(gòu)域。TFR2基因的突變與遺傳性III型血色素沉著癥有關(guān)。此外,TFR2參與通過(guò)內(nèi)吞作用將轉(zhuǎn)鐵蛋白結(jié)合的鐵攝取到細(xì)胞中,盡管與轉(zhuǎn)鐵蛋白受體1相比,其作用較小。
關(guān)鍵字: Transferrin R2;Transferrin R2蛋白;TFR2蛋白;ACRO;百普賽斯;
百普賽斯集團(tuán)ACROBiosystems Group(股票代碼:301080)是成立于2010年的跨國(guó)生物科技公司,是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺(tái)型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團(tuán)業(yè)務(wù)遍布全球,橫跨亞洲、北美洲、歐洲,在中國(guó)、美國(guó)、瑞士等12個(gè)城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計(jì)服務(wù)客戶超6000家,與全球Top 20醫(yī)藥企業(yè)均建立了長(zhǎng)期、穩(wěn)定的合作伙伴關(guān)系。集團(tuán)旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。